A new method for measurement of (−)‐sophocarpine, a candidate therapeutic for viral myocarditis, in plasma: application to a toxicokinetic study in beagle dogs
- 9 September 2005
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 19 (19) , 2840-2848
- https://doi.org/10.1002/rcm.2132
Abstract
The naturally occurring alkaloid (−)‐sophocarpine (SC) has been developed as a novel anti‐coxsackieviral agent for potential treatment of viral myocarditis. However, there is currently no rapid, sensitive method available for ascertaining systemic exposure during the course of SC toxicity studies. The development and full validation of the first rapid and sensitive method, based on liquid chromatography with tandem mass spectrometry (LC/MS/MS), for determination of SC in plasma is reported here. This new assay increases sample throughput by using minimal sample clean‐up procedures and short chromatographic analysis times. The bio‐matrix effect on the ionization of SC and the internal standard, (−)‐stepholidine, was investigated for method development and validation, and two organic solvents (methyl tert‐butyl ether and ethyl acetate) were found for sample preparation that led to low matrix effects. The new analytical method was used to analyze plasma samples obtained from a repeated‐dose toxicity study of SC in beagle dogs. The results of the toxicokinetic analysis indicated that the systemic exposure to SC was proportional to the dose, and that no significant accumulation of SC was observed after 3 months of repeated treatments with intravenous SC at 7.5, 15, or 30 mg/kg/day. This sensitive and specific LC/MS/MS technique can form the basis for accurate quantification of SC in various biological fluids for preclinical and clinical pharmacokinetic evaluation. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 16 references indexed in Scilit:
- Coxsackieviral replication and pathogenicity: lessons from gene modified animal modelsMedical Microbiology and Immunology, 2004
- Inhibition of coxsackie B3 virus induced myocarditis in mice by 2‐(3,4‐dichlorophenoxy)‐5‐nitrobenzonitrileJournal of Medical Virology, 2003
- Quantitative characterization of differential ion suppression on liquid chromatography/atmospheric pressure ionization mass spectrometric bioanalytical methodsRapid Communications in Mass Spectrometry, 2002
- The group B coxsackieviruses and myocarditisReviews in Medical Virology, 2001
- MyocarditisNew England Journal of Medicine, 2000
- Mechanistic investigation of ionization suppression in electrospray ionizationPublished by American Chemical Society (ACS) ,2000
- Pancreatic expression of interferon-γ protects mice from lethal coxsackievirus B3 infection and subsequent myocarditisNature Medicine, 2000
- The Immune System in Viral MyocarditisCirculation Research, 1999
- Treatment of viral myocarditis with focus on captoprilThe American Journal of Cardiology, 1996
- Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation.Proceedings of the National Academy of Sciences, 1992